These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39298719)

  • 21. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
    Shi Y; Fang J; Zhou C; Liu A; Wang Y; Meng Q; Ding C; Ai B; Gu Y; Yao Y; Sun H; Guo H; Zhang C; Song X; Li J; Xu B; Han Z; Song M; Tang T; Chen P; Lu H; Shui Y; Lou G; Zhang D; Liu J; Liu X; Liu X; Gao X; Zhou Q; Chen M; Zhao J; Zhong W; Xu Y; Wang M
    Thorac Cancer; 2022 Feb; 13(3):412-422. PubMed ID: 34935288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
    Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
    JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
    Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
    Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
    Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
    Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
    Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
    Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.
    Haraguchi M; Nakao Y; Narita S; Matsumoto K; Fukushima M; Sasaki R; Honda T; Miuma S; Miyaaki H; Nakao K
    Cancer Med; 2023 May; 12(9):10636-10646. PubMed ID: 36934436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
    Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
    Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.
    Liu R; Zhao H; Lu Z; Zeng L; Shi H; Wu L; Wang J; Zhong F; Liu C; Zhang Y; Qiu Z
    Clin Exp Med; 2024 Sep; 24(1):216. PubMed ID: 39249163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.
    Liu Q; Liu M; Zou Z; Lin J; Zhang N; Zhao L; Zhou J; Zhou H; Zhou X; Jiao X; Yu Y; Liu T
    J Transl Med; 2024 Aug; 22(1):803. PubMed ID: 39210332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
    Assoumou L; Baldé R; Katlama C; Abbar B; Delobel P; Allegre T; Lavole A; Makinson A; Zaegel-Faucher O; Greillier L; Soulie C; Veyri M; Bertheau M; Algarte Genin M; Gibowski S; Marcelin AG; Bihan K; Baron M; Costagliola D; Lambotte O; Spano JP
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39179255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.
    Serino M; Freitas C; Martins M; Ferreira P; Cardoso C; Veiga F; Santos V; Araújo D; Novais-Bastos H; Magalhães A; Queiroga H; Fernandes G; Hespanhol V
    Pulmonology; 2024; 30(4):352-361. PubMed ID: 35414494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors.
    Sumimoto H; Noda S; Koide H; Douke Y; Sakai K; Nishikawa A; Tomioka A; Hori M; Nakato H; Kimura Y; Tokuda A; Takano A; Teramoto K; Murata S; Daigo Y
    PLoS One; 2024; 19(7):e0306995. PubMed ID: 39012903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
    Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
    Front Immunol; 2022; 13():931429. PubMed ID: 36248782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.